Mebendazole


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Ascariasis; Hookworm infections; Trichuriasis 100 mg bid for 3 consecutive days or 500 mg as single dose. Enterobiasis 100 mg as single dose; may repeat if necessary 2-3 weeks after initial treatment.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Pregnancy.
Special Precautions
Prolonged use. Hepatic impairment. Lactation. Children < 2 years. Monitoring Parameters Monitor blood count on higher doses and prolonged duration. Periodic assessment of haematologic, hepatic and renal function. Check for helminth ova in faeces within 3-4 weeks following initial therapy.
Adverse Reactions
Significant: Bone marrow suppression e.g. agranulocytosis, neutropenia. Gastrointestinal disorders: Diarrhoea, flatulence, abdominal pain, anorexia, nausea, vomiting. Hepatobiliary disorders: Hepatitis, abnormal liver tests. Nervous system disorder: Convulsion, headache, dizziness. Skin and subcutaneous tissue disorders: Exanthema, angioedema, urticaria, alopecia, rash.
Potentially Fatal: Toxic epidermal necrolysis, Stevens-Johnson syndrome.
Drug Interactions
Increased plasma concentration with cimetidine. Decreased serum concentration with carbamazepine, fosphenytoin, phenytoin.
CIMS Class
ATC Classification
P02CA01 - mebendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
Disclaimer: This information is independently developed by CIMS based on mebendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in